Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPepGen Ltd

PepGen Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
5.7501 USD 3.36 ( 140.59%)
Last update at 2026-11-10T14:57:00Z
VOLUME
59427999
Market Cap
470.05M

Momentum Score

…

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.15
Low
6.49
High
52 Week Price Range
3.72
Low
17.51
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

PepGen Ltd is a clinical-stage biotechnology company developing oligonucleotide-based therapeutics using a proprietary delivery chemistry to address neuromuscular and central nervous system genetic diseases. Its long-term growth drivers include clinical progress of lead programs, platform licensing or partnerships and demand for treatments in rare genetic disorders, which may benefit shareholders if trials demonstrate safety and efficacy.

The principal risks are program-level clinical and regulatory failure, limited operating history and the need for additional financing to advance development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.39
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.19
ROE
-46.72%
Net Debt
-60.67M
ROCE
-54.81%
Diluted EPS TTM
-3.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -65.40M -27.28M -1.89M -
Net income -69.10M -27.28M -1.88M -
Selling general administrative 14.22M 8.11M 0.85M -
Reconciled depreciation 0.49M 0.18M 0.11M -
Ebit -68.79M -27.11M -1.88M -1.35M
Ebitda -68.30M -26.93M -1.77M -
Depreciation and amortization 0.49M 0.18M 0.11M -
Non operating income net other 2.90M - - -
Operating income -68.30M -27.11M -1.88M -
Other operating expenses 68.30M 27.11M 1.88M -
Interest expense 3.40M 0.17M 0.01M 0.00M
Tax provision 3.71M - - -
Interest income 2.79M 0.00M 0.01M -
Net interest income 2.79M 0.00M 0.01M -
Income tax expense 3.71M 0.17M -0.01M -
Total revenue 0.00M 0.00M 0.00M -
Total operating expenses 68.30M 27.11M 1.88M -
Total other income expense net 2.90M -0.17M -0.01M -
Net income from continuing ops -69.10M -27.28M -1.89M -
Net income applicable to common shares -69.10M -27.28M -4.08M -1.35M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 143.05M 217.44M 143.64M 10.64M -
Other current assets 2.27M 4.27M 2.35M 0.13M -
Total liab 34.63M 37.81M 10.55M 0.87M -
Total stockholder equity 108.42M 179.63M 133.09M 9.77M -
Deferred long term liab - - 1.50M - -
Other current liab 13.52M 11.91M 7.08M 0.12M -
Common stock 0.00M 0.00M - - -
Capital stock 0.00M 0.00M 165.18M 16.13M -
Retained earnings -181.48M -102.86M -33.75M -6.47M -2.39M
Other assets 0.00M 1.47M 3.02M - -
Cash 80.77M 181.75M 132.90M 9.78M -
Total current liabilities 17.53M 18.83M 10.32M 0.84M 0.33M
Current deferred revenue 0.00M - - - -
Net debt -60.67M -157.22M -132.90M -9.78M -
Short term debt 3.00M 5.55M - - -
Short long term debt total 20.10M 24.53M - - -
Other stockholder equity 146.81M 65.13M 1.65M 0.12M -0.01M
Property plant equipment - 3.33M 0.64M 0.32M 0.42M
Total current assets 112.68M 186.08M 139.99M 10.32M 3.77M
Net tangible assets - 179.63M -32.08M -6.36M 3.87M
Short term investments 29.63M - - - -
Net receivables - 0.06M 4.74M 0.41M 0.23M
Accounts payable 1.00M 1.36M 3.24M 0.72M 0.14M
Accumulated other comprehensive income 0.03M -0.08M 0.02M -0.01M -
Common stock total equity - 0.00M - - -
Retained earnings total equity - -102.86M - - -
Non currrent assets other 0.44M 1.47M 3.02M - -
Non current assets total 30.37M 31.36M 3.65M 0.32M -
Capital lease obligations 20.10M 24.53M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -3.75M -0.50M -0.01M -
Change to liabilities 4.12M 2.51M 0.33M 0.06M
Total cashflows from investing activities -3.75M -0.50M -0.01M -0.03M
Total cash from financing activities 112.19M 147.66M 7.95M 2.79M
Change to operating activities 1.73M 4.61M -0.15M 0.41M
Net income -69.10M -27.28M -1.89M -1.35M
Change in cash 48.86M 124.59M 6.29M 1.94M
Begin period cash flow 134.37M 9.78M 3.49M -
End period cash flow 183.22M 134.37M 9.78M 3.49M
Total cash from operating activities -59.27M -22.60M -1.65M -0.89M
Issuance of capital stock 114.27M 149.04M 7.96M -
Depreciation 0.49M 0.18M 0.11M 0.11M
Change to account receivables 4.18M -4.34M -0.17M -0.11M
Sale purchase of stock 114.89M - - -
Other cashflows from financing activities -2.07M 147.66M 7.95M -0.00M
Change to netincome 4.84M 1.73M 0.12M 0.12M
Capital expenditures 3.75M 0.50M 0.01M 0.03M
Change receivables 4.18M - - -
Cash flows other operating -3.80M - - -
Cash and cash equivalents changes 49.17M - - -
Change in working capital 4.51M 2.77M 0.01M -
Stock based compensation 4.76M 1.53M 0.12M -
Other non cash items 0.08M 0.20M - -
Free cash flow -63.02M -23.10M -1.66M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
PEPG
PepGen Ltd		 3.36
140.59%		 5.75 - - - 3.89 -3.95
NVO
Novo Nordisk A/S		 -0.70
1.70%		 40.67 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.79
0.14%		 550.08 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -6.17
0.67%		 913.79 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

PepGen Ltd

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

321 Harrison Avenue, Boston, MA, United States, 02118

781 797 0979

https://pepgen.com

65

Name Title Year Born
Dr. James G. McArthur Ph.D. Pres, CEO, Treasurer, Sec. & Director 1962
Ms. Caroline Godfrey Ph.D. Founder & Scientific Advisory Board Member NA
Mr. Noel Donnelly M.B.A. Chief Financial Officer 1970
Dr. Jaya Goyal Ph.D. Exec. VP of Research & Preclinical Devel. 1968
Dr. Michael Gait Founder & Scientific Advisory Board Member NA
Dr. Sonia Bracegirdle DPHIL Sr. VP of Strategy & Operations 1986
Ms. Jennifer Cormier Sr. VP of Clinical Operations NA
Dr. Michelle L. Mellion M.D. Sr. VP & Head of Clinical Devel. 1976
Mr. Niels Svenstrup Ph.D. Sr. VP of Chemistry, Manufacturing & Control 1970
Mr. Kyle Breidenstine VP of Fin. & Controller NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

No data available
No data available

Equity Sectors*

  • Basic Materials

    -2.54%

  • Communication Services

    +0.09%

  • Consumer Cyclical

    -0.16%

  • Consumer Defensive

    -0.14%

  • Energy

    -1.11%

  • Financial Services

    +0.15%

  • Healthcare

    -0.77%

  • Industrials

    -0.93%

  • Real Estate

    -0.17%

  • Technology

    -0.09%

  • Utilities

    -0.67%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…